2N53
 
 | | Solution structure of ovis aries prp | | Descriptor: | Major prion protein | | Authors: | Munoz, C, Egalon, A, Beringue, V, Rezaei, H, Dron, M, Sizun, C. | | Deposit date: | 2015-07-06 | | Release date: | 2016-05-25 | | Last modified: | 2023-06-14 | | Method: | SOLUTION NMR | | Cite: | Generating Bona Fide Mammalian Prions with Internal Deletions.
J.Virol., 90, 2016
|
|
2MV8
 | | Solution structure of Ovis Aries PrP with mutation delta190-197 | | Descriptor: | Major prion protein | | Authors: | Munoz, C, Egalon, A, Beringue, V, Rezaei, H, Dron, M, Sizun, C. | | Deposit date: | 2014-09-25 | | Release date: | 2015-10-07 | | Last modified: | 2023-12-27 | | Method: | SOLUTION NMR | | Cite: | Generating Bona Fide Mammalian Prions with Internal Deletions.
J.Virol., 90, 2016
|
|
2MV9
 | | Solution structure of Ovis Aries PrP with mutation delta193-196 | | Descriptor: | Major prion protein | | Authors: | Munoz, C, Egalon, A, Beringue, V, Rezaei, H, Dron, M, Sizun, C. | | Deposit date: | 2014-09-25 | | Release date: | 2015-10-07 | | Last modified: | 2023-12-27 | | Method: | SOLUTION NMR | | Cite: | Generating Bona Fide Mammalian Prions with Internal Deletions.
J.Virol., 90, 2016
|
|
1TQB
 | | Ovine recombinant PrP(114-234), VRQ variant in complex with the Fab of the VRQ14 antibody | | Descriptor: | VRQ14 Fab Heavy chain, VRQ14 Fab light chain, prion protein | | Authors: | Eghiaian, F, Grosclaude, J, Debey, P, Doublet, B, Treguer, E, Rezaei, H, Knossow, M. | | Deposit date: | 2004-06-17 | | Release date: | 2004-07-06 | | Last modified: | 2011-07-13 | | Method: | X-RAY DIFFRACTION (2.55 Å) | | Cite: | Insight into the PrPC-->PrPSc conversion from the structures of antibody-bound ovine prion scrapie-susceptibility variants
Proc.Natl.Acad.Sci.USA, 101, 2004
|
|
1TPX
 | | Ovine recombinant PrP(114-234), ARQ variant in complex with the Fab of the VRQ14 antibody | | Descriptor: | major prion protein, the VRQ14 Fab | | Authors: | Eghiaian, F, Grosclaude, J, Lesceu, S, Debey, P, Doublet, B, Treguer, E, Rezaei, H, Knossow, M. | | Deposit date: | 2004-06-16 | | Release date: | 2004-07-06 | | Last modified: | 2011-07-13 | | Method: | X-RAY DIFFRACTION (2.56 Å) | | Cite: | Insight into the PrPC -> PrPSc conversion from the structures of antibody-bound ovine prion scrapie-susceptibility variants.
Proc.Natl.Acad.Sci.USA, 101, 2004
|
|
1TQC
 | | Ovine recombinant PrP(114-234), ARR variant in complex with the VRQ14 Fab fragment (IgG2a) | | Descriptor: | VRQ14 Fab Heavy chain, VRQ14 Fab light chain, prion protein | | Authors: | Eghiaian, F, Grosclaude, J, Lesceu, S, Debey, P, Doublet, B, Treguer, E, Rezaei, H, Knossow, M. | | Deposit date: | 2004-06-17 | | Release date: | 2004-07-06 | | Last modified: | 2011-07-13 | | Method: | X-RAY DIFFRACTION (2.8 Å) | | Cite: | Insight into the PrPC-->PrPSc conversion from the structures of antibody-bound ovine prion scrapie-susceptibility variants
Proc.Natl.Acad.Sci.USA, 101, 2004
|
|
4XV2
 | |
4XV3
 | | B-Raf Kinase V600E oncogenic mutant in complex with PLX7922 | | Descriptor: | N'-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-N-ethyl-N-methylsulfuric diamide, Serine/threonine-protein kinase B-raf | | Authors: | Zhang, Y, Zhang, C. | | Deposit date: | 2015-01-26 | | Release date: | 2015-10-28 | | Last modified: | 2024-02-28 | | Method: | X-RAY DIFFRACTION (2.8 Å) | | Cite: | RAF inhibitors that evade paradoxical MAPK pathway activation.
Nature, 526, 2015
|
|
4XV9
 | | B-Raf Kinase domain in complex with PLX5568 | | Descriptor: | N-{3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl}-4-(trifluoromethyl)benzenesulfonamide, SULFATE ION, Serine/threonine-protein kinase B-raf | | Authors: | zhang, Y, zhang, c, wang, w. | | Deposit date: | 2015-01-26 | | Release date: | 2015-10-28 | | Last modified: | 2024-02-28 | | Method: | X-RAY DIFFRACTION (2 Å) | | Cite: | RAF inhibitors that evade paradoxical MAPK pathway activation.
Nature, 526, 2015
|
|
4XV1
 | | B-Raf Kinase V600E oncogenic mutant in complex with PLX7904 | | Descriptor: | N'-(3-{[5-(2-cyclopropylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl}-2,4-difluorophenyl)-N-ethyl-N-methylsulfuric diamide, Serine/threonine-protein kinase B-raf | | Authors: | Zhang, Y, Zhang, C. | | Deposit date: | 2015-01-26 | | Release date: | 2015-10-28 | | Last modified: | 2024-02-28 | | Method: | X-RAY DIFFRACTION (2.47 Å) | | Cite: | RAF inhibitors that evade paradoxical MAPK pathway activation.
Nature, 526, 2015
|
|
2KTM
 | | Solution NMR structure of H2H3 domain of ovine prion protein (residues 167-234) | | Descriptor: | Major prion protein | | Authors: | Pastore, A, Adrover, M, Pauwels, K, de Chiara, C, Prigent, S, Rezeai, H. | | Deposit date: | 2010-02-04 | | Release date: | 2010-04-07 | | Last modified: | 2021-11-10 | | Method: | SOLUTION NMR | | Cite: | Prion fibrillization is mediated by a native structural element that comprises helices H2 and H3.
J.Biol.Chem., 285, 2010
|
|
7KHJ
 | | Crystal structure of KIT kinase domain with a small molecule inhibitor, PLX8512 in the DFG-in state | | Descriptor: | 2-phenyl-5-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine, Mast/stem cell growth factor receptor Kit | | Authors: | Zhang, Y. | | Deposit date: | 2020-10-21 | | Release date: | 2021-07-07 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (2.8 Å) | | Cite: | Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial.
Jama Oncol, 7, 2021
|
|
7KHK
 | |
7KHG
 | | Crystal structure of KIT kinase domain with a small molecule inhibitor, PLX3397 | | Descriptor: | 5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-{[6-(trifluoromethyl)pyridin-3-yl]methyl}pyridin-2-amine, Mast/stem cell growth factor receptor Kit | | Authors: | Zhang, Y. | | Deposit date: | 2020-10-21 | | Release date: | 2021-07-07 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (2.15 Å) | | Cite: | Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial.
Jama Oncol, 7, 2021
|
|
5WMG
 | | N-terminal bromodomain of BRD4 in complex with OTX-015 | | Descriptor: | 1,2-ETHANEDIOL, 4-{6-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1S)-1-(pyridin-2-yl)ethyl]-1H-pyrrolo[3,2-b]pyridin-3-yl}benzoic acid, Bromodomain-containing protein 4 | | Authors: | Zhang, Y. | | Deposit date: | 2017-07-28 | | Release date: | 2018-08-01 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (1.19 Å) | | Cite: | BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.
Cancer Discov, 8, 2018
|
|
5WMD
 | | N-terminal bromodomain of BRD4 in complex with OTX-015 | | Descriptor: | 2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide, Bromodomain-containing protein 4 | | Authors: | Zhang, Y. | | Deposit date: | 2017-07-28 | | Release date: | 2018-08-01 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (1.27 Å) | | Cite: | BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.
Cancer Discov, 8, 2018
|
|
5WMA
 | | N-terminal bromodomain of BRD4 in complex with PLX5981 | | Descriptor: | 1,2-ETHANEDIOL, 5-(3,5-dimethyl-1,2-oxazol-4-yl)-1H-pyrrolo[2,3-b]pyridine, Bromodomain-containing protein 4 | | Authors: | Zhang, Y. | | Deposit date: | 2017-07-28 | | Release date: | 2018-08-01 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (1.401 Å) | | Cite: | BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.
Cancer Discov, 8, 2018
|
|
